NCT00002236View on ClinicalTrials.gov

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Indinavir sulfate

DRUG

Delavirdine mesylate

DRUG

Zidovudine

Trial Locations (6)

10019

Saint Luke's - Roosevelt Hosp Ctr, New York

15213

Anderson Clinical Research, Pittsburgh

22203

Infectious Disease Physicians Inc, Annandale

38165

Univ of Tennessee / Div of Infect Dis / Dept of Med, Memphis

90027

AIDS Healthcare Foundation, Los Angeles

94105

UCSF AIDS Research Institute, San Francisco

All Listed Sponsors

lead

Pharmacia and Upjohn

INDUSTRY

NCT00002236 - A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients | Biotech Hunter | Biotech Hunter